文献速递耳科与耳神经

助听器服务模式、技术与患者结局:一项随机临床试验

Hearing Aid Service Models, Technology, and Patient Outcomes: A Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

该随机临床试验纳入245例55岁以上轻中度听力损失且无既往助听器使用经验的成人,随机分为3种服务模式与2种技术水平的6个平行组,主要结局为生态瞬时评估的格拉斯哥助听器获益概况(EMA-GHABP)。结果显示,听力学家验配(AUD)组的EMA-GHABP全局评分显著高于非处方(OTC+)组和非处方(OTC)组,而OTC+与OTC之间无显著差异;技术水平和交互作用无显著效应。

要点

  • AUD组EMA-GHABP全局评分较OTC+组高0.33分(95%CI 0.14-0.52),较OTC组高0.32分(95%CI 0.13-0.51)。
  • OTC+与OTC之间EMA-GHABP全局评分差异无统计学意义(0.02分,95%CI -0.21至0.18)。
  • 技术水平和(服务模式×技术水平)交互作用对EMA-GHABP全局评分均无显著效应。

核心结论

  • 试验结果提示,OTC+和OTC虽有效,但未达到与AUD相同的结局。
  • 高端与低端助听器结局相似,未发现支持轻中度听力损失者承担高端助听器更高费用的证据。

研究设计与样本

  • 该研究为随机临床试验,于2019年2月至2023年12月在爱荷华大学和范德堡大学医学中心的研究实验室开展。
  • 纳入年龄大于55岁、轻中度听力损失且无既往助听器使用经验的成人,随机分配至3种服务模式与2种技术水平的6个平行组。
  • 共245例完成研究(女性121例[49.4%];平均[SD]年龄67.7[8.1]岁);数据分析于2024年1月至2024年3月进行。
  • 3种服务模式:AUD(听力学家按最佳实践验配处方助听器)、OTC+(听力学家为OTC助听器提供有限服务)、OTC(参与者独立使用OTC助听器);OTC助听器使用处方助听器模拟。
  • 2种技术水平:高端助听器(具先进功能)与低端助听器;主要结局为生态瞬时评估(EMA)实施的格拉斯哥助听器获益概况(GHABP),于干预前及干预后第7周内进行。

主要发现

  • 控制干预前评分后,AUD组干预后EMA-GHABP全局评分(范围1至5)显著高于OTC+组0.33分(95%CI 0.14-0.52),显著高于OTC组0.32分(95%CI 0.13-0.51)。
  • OTC+与OTC之间EMA-GHABP全局评分差异无统计学意义(0.02分,95%CI -0.21至0.18)。
  • OTC+和OTC的EMA-GHABP全局评分接近4分,提示结局积极。
  • 技术水平的效应以及服务模式与技术水平之间的交互作用均无统计学意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The poor affordability of hearing aids (HAs) limits their adoption. To justify higher costs, HAs fitted by audiologists (AUD service model) and high-end HAs should deliver better outcomes than over-the-counter (OTC) service models and low-end HAs. OBJECTIVE: To determine the effect of HA service models (AUD, OTC, and a hybrid OTC+ model) and technology levels (high end and low end) on patient outcomes. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted at the University of Iowa and Vanderbilt University Medical Center in research laboratories from February 2019 to December 2023 and included adults older than 55 years with mild to moderate hearing loss and no previous HA experience who were randomly assigned to 1 of 6 parallel groups, representing factorial combinations of 3 service models and 2 technology levels. The data were analyzed between January 2024 and March 2024. INTERVENTIONS: The trial included 3 service models: AUD, in which audiologists fitted prescription HAs following best practices; OTC+, in which audiologists provided limited services for OTC HAs; and OTC, in which participants independently used OTC HAs. OTC HAs were simulated using prescription HAs. Two models of prescription HAs were used throughout the trial: a high-end HA with advanced features and a low-end HA. MAIN OUTCOMES AND MEASURES: The primary outcome measure was the Glasgow Hearing Aid Benefit Profile (GHABP), which was administered using ecological momentary assessment (EMA). EMA-GHABP was conducted preintervention and throughout the seventh week postintervention. RESULTS: A total of 245 participants completed the study (121 women [49.4%]; mean [SD] age, 67.7 [8.1] years). After controlling for preintervention scores, the postintervention EMA-GHABP global score (ranging from 1 to 5) for AUD was significantly higher (indicating better outcomes) than for OTC+ and OTC by 0.33 points (95% CI, 0.14-0.52) and 0.32 points (95% CI, 0.13-0.51), respectively. The difference between OTC+ and OTC was not significant (0.02 points, 95% CI, -0.21 to 0.18). Nevertheless, EMA-GHABP global scores for OTC+ and OTC were close to 4 points, indicating positive outcomes. The effect of technology level and interaction between service model and technology level were not significant. CONCLUSIONS AND RELEVANCE: The trial results suggest that while OTC+ and OTC were effective, they did not achieve the same outcomes as AUD. As high-end and low-end HAs yielded similar outcomes, support for the higher cost of high-end HAs was not identified for individuals with mild to moderate hearing loss. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03579563.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Wu YH, Stangl E, Branscome K, et al. Hearing Aid Service Models, Technology, and Patient Outcomes: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40372746. doi:10.1001/jamaoto.2025.1008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。